



CENTER FOR DRUG DISCOVERY AND DEVELOPMENT (C3D)

Expertise

- Hit identification
- Hit to Lead
- Preclinical pharmacology profiling
- Toxicology
- Early-ADME
- Medicinal chemistry
- Non regulatory and regulatory preclinical development


Instrumentation

- Automated liquid handling (robotic platform TECAN EVO150)
- Multi-technology microplate readers (96 – 384 wells)
- HPLC chains coupled to mass spectrometers
- HP D300 dispenser for titration (TECAN)
- Cell culture room
- HCS platform: operetta CLS Perkin Elmer



Chemical libraries

- Prestwick library, 1200 FDA approved compounds
- Core library of 52 000 « drug like » compounds
- Protein/protein inhibition library: 13 000 compounds
- Natural like compounds: 1200
- Kinase library (approved or under development drugs): 590 compounds

The C3D, Center for Drug Discovery and Development is an academic drug discovery team created to **fill the translational gap in oncology between fundamental research and patients.**



The aim of this platform is to develop drug discovery programs based on validated targets or biological pathways identified by basic researchers. The mission of the C3D is thus to provide research teams with the means and technical support to identify, characterize and develop new therapies (antibodies or small molecules). The C3D focuses on the early stages of exploratory research, up until entry into clinical trials.




The C3D can support you:

- To mature your project
- To validate your target
- To manage your drug discovery program from hits identification up to the clinic
- To decipher the mechanism of action of your compound
- To validate your biomarker

Approaches:

- New chemical entity development
- Drug repurposing
- Combo screening





Access details


We support your drug discovery project at every developmental stage

- Target validation
- Screening
- Hit to lead
- Lead optimization

Mention us in your publications!

To allow our platform to pursue its objectives, we need you to mention our work in your publications as follows:

Centre for drug discovery and development, Synergie Lyon Cancer, Lyon, France. Département de recherche translationnelle et d'innovations, Centre Léon Bérard, Lyon, France



Contacts

Stéphane Giraud

CENTRE LÉON BERARD

Cheney B building, 3rd floor
28, rue Laënnec - F-69008 Lyon

stephane.giraud@lyon.unicancer.fr

Project management



Core activities

- Biology**
 - Biochemical assays
 - Enzyme assays; protein-protein interaction; Binding assays
 - Cell based assays (viability, gene reporter and apoptosis assays)
 - High Content Screening; phenotypic assays
 - Disease relevant assays
- Biophysics**
 - Bio-layer interferometry
 - NMR
- Medical Chemistry**
 - Compounds design and synthetic chemistry management
 - Structure Activity Relationship study
 - Activity, PK and Safety optimization based on biology and ADMET
- ADMET**
 - Charge (pKa), lipophilicity (logP/logD), solubility, permeability
 - Metabolism (liver microsomes, hepatocytes)
 - CYP450 inhibition; cardiac toxicity (in vitro hERG)



Stéphane Giraud

– Scientific director and manager of the platform

- › *PhD in biology with more than 12 years of experience in multidisciplinary drug discovery projects undertaken in an international environment.*
- › *Over 10 years of experience in leading and managing of a research group.*
- › *Member of steering and strategic committees / ANR (National Research Agency) expert.*
- › *Business development, funding of research and innovation.*

Submission form and more infos:

www.cancer-research-lyon.com